Outlook Therapeutics

1D
1W
1M
3M
1Y
5Y

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell OTLK and other ETFs, options, and stocks.

About OTLK

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. 

CEO
C. Russell Trenary
CEOC. Russell Trenary
Employees
17
Employees17
Headquarters
Iselin, New Jersey
HeadquartersIselin, New Jersey
Founded
2010
Founded2010
Employees
17
Employees17

OTLK Key Statistics

Market cap
297.73M
Market cap297.73M
Price-Earnings ratio
Price-Earnings ratio
Dividend yield
Dividend yield
Average volume
731.84K
Average volume731.84K
High today
$1.17
High today$1.17
Low today
$1.11
Low today$1.11
Open price
$1.13
Open price$1.13
Volume
471.39K
Volume471.39K
52 Week high
$2.12
52 Week high$2.12
52 Week low
$0.6839
52 Week low$0.6839

OTLK Earnings

-$0.09
-$0.06
-$0.03
$0.00
Q3 FY21
Q4 FY21
Q1 FY22
Q2 FY22
Q3 FY22
Q4 FY22
Q1 FY23
Estimated
-$0.04 per share
Estimated-$0.04 per share
Actual
Expected Feb 14, Pre-Market
ActualExpected Feb 14, Pre-Market
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.